Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559
For more info: http://ivcm.realpennies.com
IVI COMMUNICATIONS INCORPORATED (OTCBB: IVCM)
IVI Communications, Inc., through its subsidiaries, operates as an Internet service provider (ISP) in the United States. It provides dialup and DSL broadband Internet access, and associated services, such as email spam and virus filtering, VoIP telephony, kid safe surfing, and Web accelerator services. The company also focuses on the acquisition, consolidation, and operation of locally branded ISPs offering dialup and nationally branded wireless Internet access to residential and business customers. IVI Communications was founded in 1995 and is based in Eureka, California.
IVCM News:
June 24 - IVI Communications, Inc. Announces Acquisition of Controlling Interest by Titan Global Holdings, Inc.
Titan Management to Lead IVI Communications
IVI Communications, Inc. (OTCBB: IVCM), announced that Titan Global Holdings, Inc. (TTGL), a high growth diversified holding company, has acquired all of IVI's outstanding Series A and B Preferred stock from the former holders. The Preferred Stock includes the right to vote a majority of IVI's shares for any action to be taken by shareholders. At the time of the Preferred Stock acquisition, IVI's sole officer and director, Charles Roodenberg resigned and members of Titan management were appointed to IVI's Board, including David Marks, Titan's Chairman and Bryan Chance, Titan's President and Chief Operating Officer. Kurt Jensen was appointed as President of IVI. Mr. Jensen currently serves as President and Chief Executive Officer of Titan's Communications Division.
There are no current plans with respect to any specific changes in IVI's business, however, it is contemplated that Titan will assist IVI in acquiring or developing business operations in complimentary communication businesses.
ABOUT TITAN GLOBAL HOLDINGS
Titan Global Holdings is a diversified holding company with a dynamic portfolio of subsidiaries spanning international telecommunications, electronics and homeland security, consumer products and energy resources and distribution.
Titan's operating divisions include the following:
1) The Titan Global Energy Division owns and operates traditional and next-generation renewable energy and fuel assets that can provide significant opportunities for growth in one of the world's largest and most critical markets.
2) Titan's Communications Division serves the communication needs of those individuals that have emigrated from their host country to the United States or other countries and plans to addresses a range of high-growth markets in the international telecommunication segments, including communication technology, platform management, international wholesale communication and the distribution of prepaid international telecommunication products.
3) Titan Global Brands designs, develops, and distributes consumer products from value categories to high end branded categories, through its existing distribution channels and new ones suitable for such products. Together, it integrates, protects and expands its consumer brand management capabilities to leverage and optimize growth across Titan's worldwide distribution channels.
4) Titan Card Services plans to capitalize on the burgeoning multibillion-dollar international prepaid money transfer sector. Titan Card Services' proprietary technology provides for convenient and efficient international money transfers.
5) Titan's Electronics and Homeland Security Division includes Titan PCB East, Inc., Titan Electronics Inc., and NEO EMS, Inc. These companies specialize in the manufacture of advanced circuit boards and other electronic products for classified military and defense department customers, and other high-tech clients.
For more info: http://wnyn.realpennies.com
WARP 9 INCORPORATED (OTCBB: WNYN)
Warp 9, Inc. provides e-commerce platforms and services for the catalog and retail industry. Its suite of software platforms are designed to help online retailers maximize the Internet channel by using Warp 9's technologies for online catalogs, e-mail marketing campaigns, and interactive visual merchandising. The company offers its products on a fully managed software-as-a-service model. Warp 9 primarily offers two proprietary software systems, Warp 9 Internet Commerce System, an enterprise-grade software system that enables catalogers and retailers to expand their operation to the Internet with customizable features for product presentation and store management; and Warp 9 Email Marketing System, a Web-based email campaign and list management system. It also offers professional services, which include online catalog design, merchandizing and optimization, order management, e-mail marketing campaign development, integration to third party payment processing and fulfillment systems, analytics, custom reporting, and strategic consultation. In addition, Warp 9's strategic marketing consultants develop, deliver, and manage programs, such as paid search advertising, search engine optimization, affiliate marketing, store optimization, and email optimization. The company was founded in 1999 and is based in Santa Barbara, California.
WNYN News:
June 23 - Warp 9 Launches Gift and Home Decor Site FarCountries.com
B2B E-Commerce site showcases flexibility of Warp 9 Internet Commerce System
Warp 9, Inc. (OTCBB: WNYN), the premier provider of robust e-commerce platforms and services, announced that its new client, Far Countries, has launched its newly redesigned and upgraded business-to-business (B2B) e-commerce site on the Warp 9 Internet Commerce System (ICS) platform.
The most notable enhancement to the www.FarCountries.com site is the new, more attractive visual design. This new look features a fresher, more attractive look, navigation redesigns, and incorporates more effective merchandising techniques on the department, thumbnail and product pages that result in more sales. The new website also features several Web 2.0 features such as:
A) Dynamic quick cart - which shows item additions to the cart immediately without changing the page the user is on and providing visual feedback for meeting supplier/product purchase minimums.
B) Adobe Flash based merchandising tiles that integrated with Warp 9's ICS transaction engine.
In addition to the aesthetic elements, the site also features custom business rules that were required for Far Countries to ensure a more streamlined operation between their customers and their suppliers. Among them are:
* Unique custom shipping calculations per supplier
* Supplier specific minimum purchase requirements
* Product and SKU based minimum purchase requirements
* Quantity price breaks and case pack calculations
Warp 9 also implemented a custom image generation tool for all product images: Far Countries need only upload a single high quality image for each product and Warp 9's system automatically creates, crops, adds matting, and optimizes all images size variants needed for the site.
"We were looking for better ways to engage our retailer members and to promote the product selection more effectively. Warp 9's platform gave us the tools to deliver this to our retailers and our suppliers. We also had many unique needs based on our specific business process flow requirements and had many items on our want/wish list. Warp 9 was able to deliver on all the requests we threw at them and came up with time and cost saving solutions for us. We were impressed and are very pleased with the end result," stated Joyce Kesler, Far Countries' Executive Vice President. "We are looking forward to being able to use all the more advanced features and search engine optimization (SEO) benefits of the Warp 9 ICS now that we have launched."
Far Countries also had Warp 9 integrate directly with their new backend Microsoft Dynamics(TM) (Navision) order management / fulfillment / financial system. This automated interface will not only make the process more seamless and timely, but also provide more information for relevant decision making capabilities to company management.
Harinder Dhillon, Warp 9's CEO said, "We have launched several B2B retailers on our platform and FarCountries.com is a good example of the flexibility our platform has in accommodating the unique business logic that every B2B retailer has. We are confident that they will be able to continue to grow their online business significantly using the ICS platform."
ABOUT FAR COUNTRIES
Far Countries has grown to become the #1 online wholesale buying website in the gift and home decor industry. From its inception, FarCountries.com has looked at its business through the eyes of independent retailers. Today, the company's strategy is to provide the independent retailer with truly unique merchandise. These are often products available exclusively online thoroughly FarCountries.com. The company's customer care representatives get enormous numbers of accolades from retailers for handling any and all of the logistics issues that arise.
For more info: http://gnta.realpennies.com
GENTA INCORPORATED (OTCBB: GNTA)
Genta Incorporated operates as a biopharmaceutical company with a diversified product portfolio that is focused on delivering products for the treatment of patients with cancer. Its research portfolio consists of two programs, DNA/RNA Medicines and Small Molecules. The company's lead compound from its DNA/RNA Medicines program is Genasense⠨oblimersen sodium) injection that is designed to block the production of a protein, known as Bcl-2, which is a fundamental cause of the inherent resistance of cancer cells to anticancer treatments, such as chemotherapy, radiation, and monoclonal antibodies. Genta Incorporated is recruiting patients to the AGENDA Trial, a global Phase III trial of Genasense in patients with advanced melanoma. Its lead drug in its Small Molecule program is Ganite⠨gallium nitrate injection), which is marketed in the United States for the treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The company also develops G4544, an oral formulation of the active ingredient in Ganite, which entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. In addition, it is developing tesetaxel, an orally absorbed, semi-synthetic taxane that is in the same drug class as paclitaxel and docetaxel. The company was founded in 1988 and is based in Berkeley Heights, New Jersey.
GNTA News:
June 24 - Genta Updates Progress of its Phase 3 Trial of Genasense in Patients with Advanced Melanoma
Clinical Study on Track to Complete Accrual in Fourth Quarter 2008
Genta Incorporated (OTCBB: GNTA) announced the presentation of a progress update from an ongoing Phase 3 trial of Genasense (oblimersen sodium) Injection, the Company's lead oncology product, in patients with advanced melanoma. The data were presented at a satellite investigator's meeting held in conjunction with the Adjuvant Melanoma Congress sponsored by the European Association of Dermato-Oncology (EADO) in Marseille, France on June 21, 2008.
AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from Genta's prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients identified by a biomarker who have not previously received chemotherapy. The co-primary endpoints of AGENDA are progression-free survival and overall survival. The trial is being led by the EADO in Europe and by the M.D. Anderson Cancer Center, Houston, TX in the U.S.
To date, more than one-third of the expected total number of patients have now been randomized onto the AGENDA trial. A total of 83 sites in 12 countries have been opened in Europe, the U.S., Canada, and Australia. Clinical characteristics of the first 70 patients accrued to AGENDA (not identified by treatment group) were shown to be similar to the biomarker-defined population accrued in the previous Phase 3 trial of Genasense, known as GM301. The incidence of serious adverse events in AGENDA has been somewhat lower, which probably reflects the routine use of prescribed supportive care for all patients, as well as the double-blind design of AGENDA compared with the open-label design of GM301. Target accrual of 300 patients is expected to complete in the fourth quarter of 2008, with initial data expected shortly thereafter.
ABOUT AGENDA
AGENDA is a global Phase 3, randomized, double-blind trial in patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from an antecedent randomized trial of Genasense combined with dacarbazine (DTIC) in patients who have not previously received chemotherapy (GM301). AGENDA employs a biomarker to define those patients who derived maximum clinical benefit during the preceding study. These patients are characterized by low-normal levels of LDH (lactate dehydrogenase), a tumor-derived enzyme that is readily detected in blood.
A scientific article that describes efficacy and safety results from GM301 can be accessed at www.jco.org/cgi/content/abstract/JCO.2006.06.0483v1.
ABOUT THE EADO
The EADO is an independent non-profit organization dedicated to the promotion, coordination, and improvement of clinical and laboratory research activities in the field of skin cancer. The organization has an European and international membership of dermatologists, oncologists and clinical as well as basic research scientists interested in the field of dermato-oncology. EADO provides leadership by formulating and disseminating quality standards and guide-lines for diagnosis and treatment of skin cancer, and it provides direction, coordination and organizations of clinical, therapeutic, and experimental trials.
ABOUT GENASENSE
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.
Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html
Sponsored by: http://www.isthemarketopen.com
RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com
